Binds Virus Or Component Or Product Thereof (e.g., Virus-associated Antigen, Etc.) Patents (Class 530/388.3)
-
Publication number: 20030022849Abstract: The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection.Type: ApplicationFiled: April 4, 2001Publication date: January 30, 2003Inventor: Gwong-Jen J. Chang
-
Publication number: 20030022155Abstract: A method of directly detecting Hepatitis C virus in a fractionated or non-fractionated serum of a patient, by detecting the virus with primers corresponding to viral RNA encoding core protein which said RNA is a light fraction of the total viral RNA, the said light fraction being isolated after ultracentrifugation in a CsCl gradient of human serum containing HCV virus, said light fraction containing most of the circulating infectious HCV virus particles, the method entailing precipitating RNA, then effecting reverse transcription, and then effecting amplification with the primers described herein.Type: ApplicationFiled: April 14, 2000Publication date: January 30, 2003Inventors: Agata Budkowska, Patrick Maillard, Jadwiga Nitkiewicz, Radu Crainic
-
Publication number: 20030013081Abstract: This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGN protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection. This invention provides a method of inhibiting HCV infection of a cell susceptible to HCV infection which comprises contacting the cell with an amount of a compound effective to inhibit binding of an HCV envelope glycoprotein to a DC-SIGNR protein present on the surface of the cell, so as to thereby inhibit HCV infection of the cell susceptible to HCV infection.Type: ApplicationFiled: June 26, 2001Publication date: January 16, 2003Inventors: William C. Olson, Paul J. Maddon
-
Patent number: 6500641Abstract: This invention relates to an expression vector wherein said expression vector comprises a polynucleotide promoter sequence, a polynucleotide encoding a signal sequence, a polynucleotide encoding an antigen protein or peptide, a polynucleotide encoding a cell binding element, and a polynucleotide polyadenylation sequence all operatively linked. More particularly, it relates to the method of eliciting an immune response directed against an antigen in a mammal comprising the steps of introducing the expression vector into a cell, expressing the vector to produce an antigen under conditions wherein the antigen is secreted from the cell, endocytosing the secreted antigen into the cell, processing the antigen, and presenting fragments to a receptor to elicit a T-cell response. In addition, this invention relates to a vaccine and a method of use. The invention also relates to the method of identifying MHC-II restricted epitopes.Type: GrantFiled: May 5, 2000Date of Patent: December 31, 2002Assignee: Wake Forest University School of MedicineInventors: Si-Yi Chen, Zhaoyang You
-
Publication number: 20020177124Abstract: The subject invention relates to a novel hepatitis B surface antigen mutant and methods of detecting this mutant, and/or antibodies thereto, in patient samples. In particular, the mutant contains a substitution of amino acid threonine for the amino acid alanine at position 123 in the amino acid sequence of the hepatitis B surface antigen (HBsAg) protein.Type: ApplicationFiled: March 30, 2001Publication date: November 28, 2002Inventors: Paul F. Coleman, Isa K. Mushahwar
-
Publication number: 20020177126Abstract: The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject.Type: ApplicationFiled: November 28, 2001Publication date: November 28, 2002Applicant: MedImmune, Inc.Inventors: James F. Young, Scott Koenig, Leslie S. Johnson
-
Publication number: 20020173035Abstract: The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatitis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector.Type: ApplicationFiled: May 15, 2002Publication date: November 21, 2002Inventors: Jong-Wook Lee, In Young Ko, Heui Keun Kang, Moo Young Song, Tae Hun Song, Chang Seok Kim
-
Patent number: 6479641Abstract: Methods for detecting human parvovirus B19 in and removing it from biological samples such as blood are disclosed, together with reagents suitable for the purpose comprising binding moieties that recognize human parvovirus B19 and/or B19-like polypeptide and form a binding complex therewith. Preferred polypeptide binding moieties are particularly disclosed.Type: GrantFiled: June 14, 2001Date of Patent: November 12, 2002Assignee: Dyax Corp.Inventor: E. Fayelle Whelihan
-
Patent number: 6479282Abstract: A cassette that functions in yeast cells allowing and controlling expression of HBc Ag, HBc Ag fragments and/or recombinant HBc Ag; a reagent for detection and/or monitoring of HBV infections that relies on a product of the cassette; processes for producing monoclonal and/or polyclonal antibodies to the product of the cassette; and processes for (1) diagnosis, (2) vaccine production, (3) vaccination, (4) pharmaceutical production and (5) treatment that rely on the product of the cassette and/or the monoclonal and/or polyclonal antibodies to the product of the cassette.Type: GrantFiled: May 9, 2001Date of Patent: November 12, 2002Assignee: Bio MerieuxInventors: Odile Letourneur, Bénédicte Watelet
-
Publication number: 20020164348Abstract: The present invention provides a viral RNA-dependent RNA polymerase pharmacophore which is characterized by binding to a conserved interface binding surfaces of a viral RNA-dependent RNA polymerase.Type: ApplicationFiled: May 22, 2001Publication date: November 7, 2002Inventors: Karla Kirkegaard, Kathy Richmond, John Lyle, Steve Schultz, Scott Hobson
-
Publication number: 20020164326Abstract: Ultra high affinity antibodies with binding affinities in the range of 1010 M−1, and even 1011 M−1 are disclosed. Such antibodies include antibodies having novel high affinity complementarity determining regions (CDRs), especially those with framework and constant regions derived from either humans or mice. Methods of preparing and screening such antibodies, as well as methods of using them to prevent and/or treat disease, especially virus-induced diseases, are also disclosed.Type: ApplicationFiled: January 26, 2001Publication date: November 7, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 6471962Abstract: Two monoclonal antibodies which neutralize all infectious bursal disease viruses are employed in the preparation of infectious bursal disease vaccines. A panel of monoclonal antibodies can be used to characterize the infectious bursal disease virus strains present, according to neutralization site characteristics.Type: GrantFiled: October 2, 1992Date of Patent: October 29, 2002Assignee: The University of MarylandInventor: David Snyder
-
Patent number: 6469143Abstract: An antigen/antibody specificity exchanger is disclosed. It comprises: A) an amino-acid sequence corresponding to an amino-acid sequence of an antibody which specifically binds to a certain antigen, including hapten, B) linked by a link to C) an amino-acid sequence to which a certain antibody binds. Also, a diagnostic reagent comprising an antigen/antibody specificity exchanger according to the invention is disclosed. Said reagent may be e.g. used instead of antisera or monoclonal antibodies in in vitro testing systems, such as immunological tests. Further, a method of treating a disease or disorder caused by a known antigen in an individual in need of an increased number of antigen-specific antibodies is disclosed. In the method a tailor-made antigen/antibody specificity exchanger of the invention is issued. Said method may be e.g. used to redirect a patient's antibodies against poliovirus to fight HIV infection in said patient.Type: GrantFiled: April 19, 2001Date of Patent: October 22, 2002Assignee: Tripep ABInventor: Matti Sällberg
-
Publication number: 20020151484Abstract: The present invention relates to nucleic acids encoding SID® polypeptides which bind selectively to a polypeptide encoded by a pathogenic strain of the hepatitis C virus, as well as to the SID® polypeptides which are encoded by said nucleic acids.Type: ApplicationFiled: August 2, 2001Publication date: October 17, 2002Inventors: Pierre Legrain, Simon Whiteside, Jerome Wojcik
-
Construction and characterization of monoclonal antibodies against western equine encephalitis virus
Publication number: 20020141997Abstract: Construction and characterization of mouse monoclonal antibodies against western equine encephalitis virus (WEE) for potential use in detection, diagnosis, and immunotherapy are disclosed. Antibodies were prepared from hybridoma cells and further characterized by ELISAs, Western blotting, isotyping, and immunoprecipitation. The antibodies were also tested for cross-reactivity to other alphaviruses, such as Sindbis virus (SIN), Venezuelan equine encephalitis virus (VEE), and eastern equine encephalitis (EEE). All antibodies bound to WEE antigen in ELISAs, whereas only a subgroup of antibodies was found to be active in Western blotting and immunoprecipitations. A subset of antibodies was found to cross-react with other alphaviruses, such as SIN, VEE, and EEE.Type: ApplicationFiled: February 27, 2001Publication date: October 3, 2002Applicant: The Minister of National DefenceInventor: Leslie P. Nagata -
Publication number: 20020143157Abstract: A new protein derived from acid hydrolyzed IgG concentrate which has a molecular weight of about 55,000, and is activated by heat within the defined narrow temperature range provides resulting product that has a protective mechanism for bacterial and viral invasion of living cells.Type: ApplicationFiled: January 30, 2001Publication date: October 3, 2002Inventors: Ralph D. Yoder, Ronald E. Strohbehn
-
Publication number: 20020136739Abstract: The fusion (F) protein, attachment (G) protein and matrix (M) protein of respiratory syncytial virus (RSV) are isolated and purified from respiratory syncytial virus by mild detergent extraction of the proteins from concentrated virus, loading the protein onto a hydroxyapatite or other ion-exchange matrix column and eluting the protein using mild salt treatment. The F, G and M proteins, formulated as immunogenic compositions, are safe and highly immunogenic and protect relevant animal models against decreased caused by respiratory syncytial virus infection.Type: ApplicationFiled: September 13, 2001Publication date: September 26, 2002Inventors: George A. Cates, Sonia E. Sanhueza, Raymond P. Oomen, Michel H. Klein
-
Patent number: 6455264Abstract: The present invention relates to a diagnostic method for the diagnosis of Pestivirus infection in animals, in particular to a method for the diagnosis of animals infected with BVDV. A monoclonal antibody directed to a conserved antigen determinant on the Pestivirus ERNS protein is provided which allows the identification of infected animals with a high sensitivity and specificity.Type: GrantFiled: February 7, 2000Date of Patent: September 24, 2002Assignee: Akzo Nobel N.V.Inventors: Judith Baumeister, Robert Stark, Matthias König, Heinz-Jürgen Thiel
-
Patent number: 6455492Abstract: Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reasing frames of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.Type: GrantFiled: April 20, 1992Date of Patent: September 24, 2002Assignee: Genelabs Technologies, Inc.Inventors: Gregory R. Reyes, Daniel W. Bradley, Jr-Shin Twu, Michael A. Purdy, Albert W. Tam, Krzysztof Z. Krawczynski, Patrice O. Yarbough
-
Publication number: 20020132228Abstract: Peripheral blood leucocytes incubated with a semi-synthetic phage antibody library and fluorochrome-labeled CD3 and CD20 antibodies were used to isolate human single chain Fv antibodies specific for subsets of blood leucocytes by flow cytometry. Isolated phage antibodies showed exclusive binding to the subpopulation used for selection or displayed additional binding to a restricted population of other cells in the mixture. At least two phage antibodies appeared to display hithereto unknown staining patterns of B lineage cells. This approach provides a subtractive procedure to rapidly obtain human antibodies against known and novel surface antigens in their native configuration, expressed on phenotypically defined subpopulations of cells. Importantly, this approach does not depend on immunization procedures or the necessity to repeatedly construct phage antibody libraries.Type: ApplicationFiled: May 24, 2001Publication date: September 19, 2002Inventors: Leon W.M.M. Terstappen, Ton Logtenberg
-
Patent number: 6451309Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: GrantFiled: February 9, 2001Date of Patent: September 17, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20020123040Abstract: The present invention relates to the isolation of the Guinea Pig Adenovirus (GPAdV) Hexon gene and the determination of the encoded polypeptide. The purified GPAdV hexon coat protein, or bioactive fragments thereof, can be used in accordance with one embodiment to detect and study the incidence and/or development of antibodies in guinea pigs exposed to GPAdV.Type: ApplicationFiled: March 1, 2002Publication date: September 5, 2002Inventors: Sanford H. Feldman, Nicholas Douris
-
Patent number: 6440416Abstract: A method of stimulating an immune response in a human against malignant cells or an infectious agent comprises the step of administering to the human an immunogenic amount of a primate anti-idiotype antibody or antibody fragment that acts as an immunogenic functional mimic of an antigen produced by or associated with a malignant cell or an infectious agent. Sub-human primate anti-idiotype antisera, especially from baboons, are preferred. Such anti-idiotype antibodies are used to make vaccines for inducing preventive immunity or a therapeutic immune response against tumors, viruses, bacteria, rickettsia, mycoplasma, protozoa, fungi and multicellular parasites.Type: GrantFiled: January 2, 1992Date of Patent: August 27, 2002Assignee: Immunomedics, Inc.Inventors: David M. Goldenberg, Hans J. Hansen
-
Publication number: 20020106639Abstract: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in a vertebrate subject. Polynucleotides derived from the viral genome can be used as diagnostic primers and probes.Type: ApplicationFiled: August 20, 2001Publication date: August 8, 2002Applicant: University of SaskatchewanInventors: Li Wang, Lorne A. Babiuk, Andrew A. Potter, Philip Willson
-
Publication number: 20020102257Abstract: This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb1129 and the use thereof for the prevention and/or treatment of RSV infection.Type: ApplicationFiled: September 21, 1998Publication date: August 1, 2002Inventor: LESLIE SID JOHNSON
-
Publication number: 20020103344Abstract: The invention concerns retrovirus envelope glycoprotein mutants characterized in that they are glycoproteins capable of specifically binding with chemokine receptors and having an inhibiting activity with respect to a retroviral infection.Type: ApplicationFiled: September 24, 2001Publication date: August 1, 2002Inventors: Francisco Veas, Franz Jansen, Dorothee Misse
-
Publication number: 20020102535Abstract: The invention provides gp38 polypeptides, which play a role in immunomodulation, nucleic acid molecules encoding these polypeptides, and therapeutic and diagnostic methods employing these polypeptides and nucleic acid molecules. The invention also provides methods for identifying compounds that modulate the biological activities of gp38 nucleic acid molecules and polypeptides, and therapeutic methods employing these compounds.Type: ApplicationFiled: October 11, 2001Publication date: August 1, 2002Inventors: Grant McFadden, Karim Essani
-
Publication number: 20020098189Abstract: High potency antibodies, including immunologically active fragments thereof, having high kinetic association rate constants and optional high affinities are disclosed, along with methods for producing such antibodies. The high potency antibodies disclosed herein are of either the neutralizing or non-neutralizing type and have specificity for antigens displayed by microorganisms, especially viruses, as well as antigenic sites present on cancer cells and on various types of toxins, and the products of toxins. Processes for producing high potency neutralizing antibodies and increasing the potency of already existing neutralizing antibodies are also described. Methods of using said antibodies in the prevention and/or treatment of diseases, especially diseases induced or caused by viruses, are disclosed.Type: ApplicationFiled: March 1, 2001Publication date: July 25, 2002Inventors: James F. Young, Leslie S. Johnson, William D. Huse, Herren Wu, Jeffry D. Watkins
-
Patent number: 6413771Abstract: A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue of human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV F-protein≦2×10−9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.Type: GrantFiled: June 18, 1999Date of Patent: July 2, 2002Assignee: IDEC Pharmaceuticals CorporationInventors: Peter Brams, Phillip R. Morrow
-
Publication number: 20020076415Abstract: The present invention provides heretofore unidentified proteins and smaller peptides of HCV, which are produced by translation of the HCV core RNA through a frameshifting mechanism. In one embodiment the invention provides a protein that is about 125 to about 161 amino acids long depending on the HCV genotypes. The smaller peptides of the invention range in length from about 13 amino acids to over 50 amino acids. The invention also includes DNA sequences that encode the polypeptides of the invention, antibodies directed against the polypeptides of the invention, and therapeutic compositions including vaccines and anti-viral compositions. Additionally, the invention provides for methods for diagnosing, preventing and treating hepatitis C using the compounds and compositions of the invention.Type: ApplicationFiled: December 14, 2000Publication date: June 20, 2002Inventors: Jing-Hsiung Ou, Zhenming Xu
-
Publication number: 20020061581Abstract: The present invention relates to a variable region of the monoclonal antibody against the S-surface antigen of hepatis B virus and a gene encoding the same, a recombinant vector containing the said gene, and a transformant obtained from the said recombinant vector.Type: ApplicationFiled: May 29, 2001Publication date: May 23, 2002Inventors: Jong Wook Lee, In Young Ko, Heui Keun Kang, Jung Hyun Nam, Moo Young Song, Hyung Jin Moon, Tae Hun Song
-
Patent number: 6372884Abstract: A method of constructing biologically active compounds which mimic the biological activity of the biologically active protein block the activity of the biologically active protein is disclosed. A method of identifying specific and discrete portions of pathogen antigens which either serve as epitopes for neutralizing antibodies or which are involved in pathogen binding to host cell receptors is disclosed. A method of constructing biologically active compounds which compete with cellular receptors for binding to either biologically active proteins or pathogen antigens is disclosed.Type: GrantFiled: November 21, 1996Date of Patent: April 16, 2002Assignee: The Trustees of the University of PennsylvaniaInventors: Mark I. Greene, William V. Williams, David B. Weiner, Jeffrey A. Cohen, Thomas Kieber-Emmons, Robert M. Williams
-
Patent number: 6365717Abstract: The present invention relates to peptides immunochemically reactive with antibodies to the Epstein-Barr virus (EBV), nucleic acid sequences encoding these peptides, monoclonal antibodies against these peptides, cell lines capable of producing monoclonal antibodies and anti-idiotype antibodies. The invention also relates to recombinant vector molecules comprising a nucleic acid sequence according to the invention and host cells transformed or transfected with these vector molecules. The invention is further concerned with immunological reagents and methods for the detection of EBV or anti-EBV antibodies and a method for the amplification and detection of Epstein Barr viral nucleic acid.Type: GrantFiled: December 4, 1998Date of Patent: April 2, 2002Assignee: Akzo Nobel, N.V.Inventors: Jaap M. Middeldorp, Wouterus M. J. van Grunsven
-
Publication number: 20020037286Abstract: The invention relates to polypeptides which form a protein complex which regulates cytoskeletal reorganization, for example, in connection with T cell activation. The invention also relates to nucleic acids that encode the polypeptides, as well as agents which bind the nucleic acids or the encoded polypeptides. Also disclosed are methods of using such nucleic acids, polypeptides and binding agents to modulate protein complex formation, actin cytoskeletal reorganization and cell activity, as well as drug discovery methods.Type: ApplicationFiled: April 3, 2001Publication date: March 28, 2002Inventors: Matthias Krause, Antonio S. Sechi, Frank B. Gertler, Jurgen Wehland
-
Publication number: 20020031761Abstract: Methods for detecting human parvovirus B19 in and removing it from biological samples such as blood are disclosed, together with reagents suitable for the purpose comprising binding moieties that recognize human parvovirus B19 and/or B19-like polypeptide and form a binding complex therewith. Preferred polypeptide binding moieties are particularly disclosed.Type: ApplicationFiled: June 14, 2001Publication date: March 14, 2002Inventor: E. Fayelle Whelihan
-
Patent number: 6350854Abstract: The invention involves an isolated anti-prion-protein binding protein that has a molecular weight of about 55 kD to about 72 kD as determined by SDS-PAGE. Also described is a peptide derived from this isolated anti-prion-protein binding protein. Diagnostic uses for each of these molecules are discussed.Type: GrantFiled: March 17, 2000Date of Patent: February 26, 2002Assignees: Ludwig Institute for Cancer Research, Fundacao Antonio PrudenteInventors: Ricardo R. Brentani, Vilma J. Martins, Sandro J. de Souza
-
Publication number: 20020009447Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: ApplicationFiled: February 9, 2001Publication date: January 24, 2002Inventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20020002272Abstract: Described herein is a method of eliciting antibodies and neutralizing of binding antibodies against a hepatitis C virus (HCV) E1E2 or E2 antigen using HCV E2 or HCV E1E2 polypeptides and/or HCV E2 or E1E2 polynucleotides. Elicitation of anti-E2 antibodies and anti-E2 NOB antibodies can be used, inter alia, to provide model systems to optimize anti-E2 antibody responses and/or anti-E2 NOB antibody responses to HCV and to provide prophylactic or therapeutic treatment against HCV infection.Type: ApplicationFiled: December 1, 2000Publication date: January 3, 2002Inventors: Michael Houghton, Mark Selby, Sergio Abrignani, Jens Martin Heile, Derek O'Hagan
-
Patent number: 6329173Abstract: The present invention relates to a method by which one can target an undesired target molecule or target antigen, preferably a protein. The method comprises the intracellular expression of an antibody capable of binding to the target. A DNA sequence is delivered to a cell, the DNA sequence contains a sufficient number of nucleotides coding for the portion of an antibody capable of binding to the target operably linked to a promoter that will permit expression of the antibody in the cell(s) of interest. The antibody is then expressed intracellularly and binds to the target, thereby disrupting the target from its normal actions.Type: GrantFiled: April 21, 2000Date of Patent: December 11, 2001Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Wayne A. Marasco, William A. Haseltine
-
Publication number: 20010049137Abstract: The invention concerns DNA fragments derived from the genomic DNA of HPV-33. These fragments are selected from the group of fragments extending between the nucleotide extremities defined hereafter in relation to the nucleotide-numbering in FIGS.Type: ApplicationFiled: April 12, 2001Publication date: December 6, 2001Applicant: INSTITUT PASTEURInventors: Stewart Cole, Rolf E. Streeck
-
Patent number: 6322794Abstract: The invention relates to seroreactive epitopes on proteins of human papillomavirus HPV18. In addition, the invention relates to peptides which have amino-acid sequences which coincide in whole or in part with the sequences of the seroreactive epitopes, and to vaccines which contain such peptides.Type: GrantFiled: December 10, 1993Date of Patent: November 27, 2001Assignee: Dade Behring Marburg GmbHInventors: Conrad Bleul, Lutz Gissmann, Martin Müller
-
Publication number: 20010031463Abstract: The invention relates to a method for purifying and concentrating AAV-2 and antigen portions thereof. AAV-2 or antigen portions thereof are bonded to an activated chromatographic material on which antibodies are linked, said antibodies being directed against AAV-2. Afterwards, elution using a solution containing 0.5 to 4.5 M MgCl2 is carried out. The invention also relates to a kit for implementing said method.Type: ApplicationFiled: June 20, 2001Publication date: October 18, 2001Inventors: Jurgen Kleinschmidt, Andrea Kern
-
Patent number: 6303755Abstract: Therapeutic multispecific compounds comprised of anti-Fc&agr; receptor antibodies and methods of use are provided.Type: GrantFiled: March 4, 1999Date of Patent: October 16, 2001Assignee: Medarex, Inc.Inventors: Yashwant M. Deo, Robert Graziano, Tibor Keler
-
Publication number: 20010027565Abstract: A 24 kd protein capable of binding the E2 envelope protein of hepatitis C virus (HCV), and functionally equivalent variants or fragments of the 24 kd protein, are disclosed. Processes for production and purification of the 24 kd protein, and functionally equivalent variants or fragments thereof, are also disclosed.Type: ApplicationFiled: January 5, 2001Publication date: October 4, 2001Applicant: Chiron S.p.A.Inventor: Sergio Abrignani
-
Patent number: 6254867Abstract: Disclosed is a process for obtaining hybridoma cell lines which produce human antibodies capable of binding to the hepatitis B virus surface antigen (HBVsAg), as well as the hybridoma cell lines, and antibodies produced by the cell lines. Also disclosed are various uses of said antibodies in the prevention and treatment of HBV infection. Peripheral blood lymphocytes obtained from human donors having a high titer of anti HBVsAg antibodies are engrafted into normal strains of mice which were lethally irradiated and radioprotected with SCID bone marrow. After immunization of such chimeric mice with HBVsAg, human cells are obtained from the mice spleens and fused in vitro with heteromyeloma cells to generate hybridomas secreting human antibodies having a high affinity and specificity to HBVsAg.Type: GrantFiled: December 10, 1998Date of Patent: July 3, 2001Assignees: Yeda Research & Development Co. Ltd, XTL Biopharmaceuticals LtdInventors: Yair Reisner, Shlomo Dagan
-
Patent number: 6238860Abstract: Methods for detecting human parvovirus B19 in and removing it from biological samples such as blood are disclosed, together with reagents suitable for the purpose comprising binding moieties that recognize human parvovirus B19 and/or B19-like polypeptide and form a binding complex therewith. Preferred polypeptide binding moieties are particularly disclosed.Type: GrantFiled: November 5, 1998Date of Patent: May 29, 2001Assignee: Dyax Corp.Inventor: E. Fayelle Whelihan
-
Patent number: 6235284Abstract: The invention relates to a polypeptide comprising a peptide sequence belonging to the sequence of the first 62 amino acids of the terminal part of the CORE (or capsid) protein of the human hepatitis C virus (HCV), the polypeptide comprising either an isolated peptide sequence that is composed of the 45 N-terminal amino acids of the core protein, with 1 to 10 amino acids optionally amputated from its N-terminal part and/or its C-terminal part, or an immunogenic sequence equivalent to the peptide sequence and exhibiting immunological cross-reactivity with the peptide sequence towards HCV. The invention also relates to a polypeptide composition, a reagent and a means for the detection of the HCV virus, a process and a device for the detection of anti-HCV antibodies, an immunotherapeutic composition and antibodies directed against HCV.Type: GrantFiled: January 30, 1995Date of Patent: May 22, 2001Assignee: Bio MerieuxInventors: Pascal Dalbon, Michel C. Jolivet
-
Patent number: 6221355Abstract: The present invention provides an anti-pathogen system comprising one or more fusion proteins that includes a transduction domain and a cytotoxic domain. The cytotoxic domain is specifically activated by a pathogen infection. The anti-pathogen system effectively kills or injures cells infected by one or a combination of different pathogens. Further provided are protein transduction domains that provide enhanced transduction efficiency.Type: GrantFiled: December 10, 1998Date of Patent: April 24, 2001Assignee: Washington UniversityInventor: Steven F. Dowdy
-
Patent number: 6210926Abstract: The ICP4 protein of herpes simplex virus plays an important role in the transactivation of viral genes. The present invention discloses that ICP4 also has the ability to inhibit apoptosis. This function appears to reside in functional domain distinct from the transactivating function, as indicated by studies using temperature sensitive mutants of ICP4 that transactivating function at elevated temperatures. Also disclosed are methods for inhibition of apoptosis using ICP4 or an ICP4 encoding gene, such as an &agr;4 gene, methods of inhibiting ICP4's apoptosis-inhibiting function, and methods for the production of recombinant proteins and treatment of HSV infections.Type: GrantFiled: March 1, 1999Date of Patent: April 3, 2001Assignee: Arch Development CorporationInventors: Rosario Leopardi, Bernard Roizman
-
Patent number: 6193981Abstract: A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, in multiple antigenic peptides or as part of recombinant proteins. Various combinations of the Epitope I through IV peptides can provide other compositions useful in eliciting anti-Tat antibodies which cross-react with multiple strains and variants of HIV-1 Tat protein.Type: GrantFiled: July 10, 1998Date of Patent: February 27, 2001Assignee: Thymon L.L.C.Inventor: Gideon Goldstein